Introduction This study aimed to systematically review clinical trial evidence on the efficacy and safety of rose hips in alleviating symptoms associated with gastrointestinal disorders. Methods A comprehensive search was conducted without time restriction up to December 2025 across major Persian and English databases, including MagIran, SID, PubMed, Google Scholar, Scopus, and ScienceDirect. Keywords related to rose hips and gastrointestinal disorders were applied. Results Of 178 initially screened records, 18 clinical trials met the eligibility criteria. Study quality was evaluated using the CONSORT 2025 checklist. Results showed that Rosehip–based interventions demonstrated therapeutic benefits across a broad spectrum of gastrointestinal disorders, including constipation, functional dyspepsia, gastroesophageal reflux disease (GERD), chemotherapy-induced nausea and vomiting, irritable bowel syndrome (IBS), and haemorrhoids. Various rose-containing formulations (eg, rose oil capsules, syrups, gels, and topical preparations) showed comparable or, in several cases, superior effectiveness relative to standard pharmacological treatments such as omeprazole, metoclopramide, lactulose, and polyethylene glycol. Significant improvements in quality of life, along with reductions in psychological symptoms such as anxiety and depression, were also reported. However, the available evidence did not support a definitive effect on Helicobacter pylori eradication. Conclusion Rose-based therapies appear to be safe and effective for managing gastrointestinal symptoms, likely due to their anti-inflammatory, antioxidant, and sedative properties, and may serve as a complementary or alternative treatment option. Nevertheless, larger, well-designed clinical trials are required to strengthen the current evidence base.
No takes yet. Share an insight, caveat, or question.
Moshfegh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: